Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial
Authors Esteve JL, Acosta R, Pérez Y, Rodriguez B, Seigler I, Sanchez C, Tomasi G
Received 15 January 2013
Accepted for publication 9 March 2013
Published 25 June 2013 Volume 2013:5 Pages 361—369
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Josep Lluis Carbonell Esteve,1 Rita Acosta,2 Yasmirian Pérez,2 Barbara Rodriguez,2 Isabel Seigler,2 Carlos Sanchez,2 Giuseppe Tomasi3
1Mediterránea Médica Clinic, Valencia, Spain; 2Eusebio Hernández Gynecology and Obstetrics Teaching Hospital, Havana, Cuba; 3University of The Basque Country, Bilbao, Spain
Objective: To evaluate the efficacy, safety, and quality of life of 5 mg mifepristone per day compared with a placebo in treating uterine fibroids.
Design: Randomized, double-blind clinical study.
Location: Eusebio Hernández Gynecology and Obstetrics Teaching Hospital, Havana, Cuba.
Subjects: One hundred twenty-four subjects with symptomatic uterine fibroids.
Treatment: One daily capsule of 5 mg mifepristone or a mifepristone placebo over 3 months.
Variables in evaluating safety: Changes in fibroid and uterine volumes, changes in symptom prevalence and intensity, and changes in quality of life.
Results: Three months into treatment, fibroid volume was reduced by 28.5% in the mifepristone group with an increase of 1.8% in the placebo group (P = 0.031). There were significant differences between the groups with respect to pelvic pain prevalence
(P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P < 0.001), and metrorrhagia (P = 0.002) at the end of treatment. Amenorrhea was 93.1% and 4.3% in the mifepristone and placebo groups, respectively (P < 0.001). Treatment side effects were significantly greater in the mifepristone group. Estradiol levels did not differ significantly between the placebo and mifepristone groups at the end of treatment. Improvement in quality of life was significantly greater in the categories of "symptoms" (P = 0.004) and "activity" (P = 0.045) in the mifepristone group.
Conclusion: The 5 mg dosage of mifepristone presented significantly superior efficacy compared to the placebo.
Keywords: mifepristone, leiomyoma, fibroid, antiprogestins
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]